PALACE 4, A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, FOR TREATMENT OF PSORIATIC ARTHRITIS: LONG-TERM (52-WEEK) IMPROVEMENTS IN PHYSICAL FUNCTION

Authors
Category Primary study
JournalANNALS OF THE RHEUMATIC DISEASES
Year 2014
This article has no abstract
Epistemonikos ID: 58c2bbfd04a9599aea37334702e04ed4e508adf7
First added on: Feb 15, 2022